Zhuhai Lituo Biotechnology Co., Ltd.

Zhuhai Lituo Biotechnology Co., Ltd. specialises in diagnostic devices primarily used in cytology and microbiology. Their products include liquid-based cytology reagents and processors, which prepare cell samples for microscopic analysis—commonly used in cervical screening. They also produce diagnostic kits for detecting *Helicobacter pylori* via urease testing, leucorrhoea staining solutions for vaginal sample examination, and automated blood culture systems to identify microbial contamination in blood. These devices support laboratory diagnostics in infectious disease and cytopathology.

Zhuhai Lituo Biotechnology Co., Ltd. is based in China. While the company’s location influences its regulatory pathways—such as compliance with Chinese medical device regulations—the specific devices it manufactures (e.g., liquid-based cytology reagents or automated blood culture systems) are authorised separately under frameworks like the EU’s MDR or IVDR if marketed in the European Union. The company’s products listed in eudamed indicate they meet EU requirements for registration, but individual device authorisations depend on their classification and risk level.

Zhuhai Lituo Biotechnology Co., Ltd.’s devices are listed in eudamed, the EU’s centralised database for medical devices. This registry is mandatory for manufacturers placing devices on the European market, as it ensures transparency about authorised products under EU regulations (e.g., MDR or IVDR). Listing here confirms the company’s devices meet EU requirements for safety, performance, and compliance, though the specific classification (Class A, B, or IVD General) determines the rigorousness of the evaluation process.

Zhuhai Lituo Biotechnology Co., Ltd.’s devices are classified as Class A, Class B, or under the IVD General category in the EU. Classification depends on risk: Class A devices (e.g., some cytology reagents) pose minimal risk, while Class B or IVD devices (e.g., *Helicobacter pylori* kits or automated blood culture systems) involve higher scrutiny due to their diagnostic impact. Higher classifications require more rigorous clinical evidence, manufacturing controls, and post-market surveillance to ensure safety and efficacy before authorisation.